Experimental assessment of inter-centre variation in stopping-power and range prediction in particle therapy.


Journal

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
ISSN: 1879-0887
Titre abrégé: Radiother Oncol
Pays: Ireland
ID NLM: 8407192

Informations de publication

Date de publication:
10 2021
Historique:
received: 15 03 2021
revised: 01 07 2021
accepted: 19 07 2021
pubmed: 31 7 2021
medline: 31 12 2021
entrez: 30 7 2021
Statut: ppublish

Résumé

Experimental assessment of inter-centre variation and absolute accuracy of stopping-power-ratio (SPR) prediction within 17 particle therapy centres of the European Particle Therapy Network. A head and body phantom with seventeen tissue-equivalent materials were scanned consecutively at the participating centres using their individual clinical CT scan protocol and translated into SPR with their in-house CT-number-to-SPR conversion. Inter-centre variation and absolute accuracy in SPR prediction were quantified for three tissue groups: lung, soft tissues and bones. The integral effect on range prediction for typical clinical beams traversing different tissues was determined for representative beam paths for the treatment of primary brain tumours as well as lung and prostate cancer. An inter-centre variation in SPR prediction (2σ) of 8.7%, 6.3% and 1.5% relative to water was determined for bone, lung and soft-tissue surrogates in the head setup, respectively. Slightly smaller variations were observed in the body phantom (6.2%, 3.1%, 1.3%). This translated into inter-centre variation of integral range prediction (2σ) of 2.9%, 2.6% and 1.3% for typical beam paths of prostate-, lung- and primary brain-tumour treatments, respectively. The absolute error in range exceeded 2% in every fourth participating centre. The consideration of beam hardening and the execution of an independent HLUT validation had a positive effect, on average. The large inter-centre variations in SPR and range prediction justify the currently clinically used margins accounting for range uncertainty, which are of the same magnitude as the inter-centre variation. This study underlines the necessity of higher standardisation in CT-number-to-SPR conversion.

Identifiants

pubmed: 34329653
pii: S0167-8140(21)06662-7
doi: 10.1016/j.radonc.2021.07.019
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

7-13

Subventions

Organisme : Cancer Research UK
Pays : United Kingdom

Informations de copyright

Copyright © 2021 The Authors. Published by Elsevier B.V. All rights reserved.

Auteurs

Nils Peters (N)

OncoRay - National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Helmholtz-Zentrum Dresden - Rossendorf, Dresden, Germany; Helmholtz-Zentrum Dresden - Rossendorf, Institute of Radiooncology - OncoRay, Dresden, Germany. Electronic address: nils.peters@oncoray.de.

Patrick Wohlfahrt (P)

OncoRay - National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Helmholtz-Zentrum Dresden - Rossendorf, Dresden, Germany; Helmholtz-Zentrum Dresden - Rossendorf, Institute of Radiooncology - OncoRay, Dresden, Germany.

Christina V Dahlgren (CV)

The Skandion Clinic, Uppsala, Sweden.

Ludovic de Marzi (L)

Institut Curie, PSL Research University, University Paris Saclay, LITO, Orsay, France; Institut Curie, PSL Research University, Radiation Oncology Department, Proton Therapy Centre, Centre Universitaire, Orsay, France.

Malte Ellerbrock (M)

Heidelberg Ion-Beam Therapy Center (HIT), Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany.

Francesco Fracchiolla (F)

Centro di Protonterapia di Trento, Trento, Italy.

Jeffrey Free (J)

University of Groningen, University Medical Center Groningen, Department of Radiation Oncology, Groningen, The Netherlands.

Carles Gomà (C)

KU Leuven, Department of Oncology, Laboratory of Experimental Radiotherapy, Leuven, Belgium.

Joanna Góra (J)

EBG Medaustron GmbH, Wiener Neustadt, Austria.

Maria F Jensen (MF)

Danish Centre for Particle Therapy, Aarhus, Denmark.

Tomasz Kajdrowicz (T)

Institute of Nuclear Physics - Polish Academy of Sciences, Krakow, Poland.

Ranald Mackay (R)

University of Manchester - Faculty of Life Sciences, Manchester, United Kingdom.

Silvia Molinelli (S)

Centro Nazionale di Adroterapia Oncologica, Pavia, Italy.

Ilaria Rinaldi (I)

Department of Radiation Oncology (Maastro), GROW School for Oncology, Maastricht University Medical Centre, Maastricht, The Netherlands.

Vasilis Rompokos (V)

University College London Hospitals, London, United Kingdom.

Dorota Siewert (D)

Paul Scherrer Institut, Villigen, Switzerland.

Pieternel van der Tol (P)

HollandPTC Protonen Therapie Centrum, Delft, The Netherlands.

Xavier Vermeren (X)

Westdeutsches Protonentherapiezentrum Essen, Universitätsklinkum Essen, Germany.

Håkan Nyström (H)

The Skandion Clinic, Uppsala, Sweden.

Antony Lomax (A)

Paul Scherrer Institut, Villigen, Switzerland.

Christian Richter (C)

OncoRay - National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Helmholtz-Zentrum Dresden - Rossendorf, Dresden, Germany; Helmholtz-Zentrum Dresden - Rossendorf, Institute of Radiooncology - OncoRay, Dresden, Germany; Department of Radiotherapy and Radiation Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Germany; German Cancer Consortium (DKTK), partner site Dresden, and German Cancer Research Center (DKFZ), Heidelberg, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH